Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment
- PMID: 12698085
- DOI: 10.1097/01.TP.0000057244.03192.BD
Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment
Abstract
Background: Previous studies have suggested an increased risk of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder (EBV-PTLD) in patients receiving tacrolimus for immunosuppression. We hypothesized that after correction for confounding variables, immunosuppression with tacrolimus is not associated with an increased risk of EBV-PTLD.
Methods: Potential cases of EBV-PTLD, identified by chart review, were independently ascertained by three clinicians and defined using published criteria. Agreement in diagnosing EBV-PTLD was measured using Kappa coefficients. Unadjusted and adjusted relative risk estimates were determined using proportional hazards regression.
Results: Twenty-three cases of EBV-PTLD were identified in 221 patients, a proportion of 10.4% (95% confidence interval [CI]: 6.4%-14.4%). Multivariable analysis revealed that immunosuppression with tacrolimus was associated with an increased risk of EBV-PTLD (relative risk 3.10: 95% CI: 1.21-7.92), as was age at transplantation as a continuous variable (parameter estimate -0.15, P=0.03). Kappa coefficients in diagnosing EBV-PTLD and subclassifying as neoplastic and non-neoplastic EBV-PTLD were 0.73 (95% CI: 0.54-0.93) and 0.54 (95% CI: 0.40-0.68), respectively. Patients with neoplastic PTLD demonstrated a lower probability of survival than patients with non-neoplastic PTLD and non-cases.
Conclusions: Immunosuppression with tacrolimus and young age at transplantation are associated with an increased risk of EBV-PTLD in children undergoing liver transplantation, although we cannot exclude detection bias as an explanation for this observed increase. Good agreement between observers can be achieved using previously published criteria for defining EBV-PTLD. Patients with neoplastic EBV-PTLD may have a worse prognosis, and thus identification of risk factors for the development of this subtype of the disorder may be more important.
Similar articles
-
Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.J Heart Lung Transplant. 2008 Jan;27(1):100-5. doi: 10.1016/j.healun.2007.09.027. J Heart Lung Transplant. 2008. PMID: 18187094
-
Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.J Heart Lung Transplant. 2010 Jun;29(6):648-57. doi: 10.1016/j.healun.2010.01.013. Epub 2010 Mar 20. J Heart Lung Transplant. 2010. PMID: 20304682
-
Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.Transplantation. 2009 Mar 15;87(5):758-62. doi: 10.1097/TP.0b013e318198d645. Transplantation. 2009. PMID: 19295323
-
Posttransplant lymphoproliferative disorder.Ann Pharmacother. 2007 Nov;41(11):1850-8. doi: 10.1345/aph.1G706. Epub 2007 Oct 16. Ann Pharmacother. 2007. PMID: 17940127 Review.
-
Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.Transpl Infect Dis. 2009 Oct;11(5):383-92. doi: 10.1111/j.1399-3062.2009.00411.x. Epub 2009 Jun 23. Transpl Infect Dis. 2009. PMID: 19558376 Review.
Cited by
-
Neoplastic disease after liver transplantation: Focus on de novo neoplasms.World J Gastroenterol. 2015 Aug 7;21(29):8753-68. doi: 10.3748/wjg.v21.i29.8753. World J Gastroenterol. 2015. PMID: 26269665 Free PMC article. Review.
-
Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.Pathol Oncol Res. 2011 Sep;17(3):443-54. doi: 10.1007/s12253-010-9329-8. Epub 2010 Dec 31. Pathol Oncol Res. 2011. PMID: 21193979 Review.
-
Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.Can J Gastroenterol Hepatol. 2015 Nov-Dec;29(8):417-22. doi: 10.1155/2015/517359. Epub 2015 Jun 15. Can J Gastroenterol Hepatol. 2015. PMID: 26076399 Free PMC article.
-
Current developments in pediatric liver transplantation.World J Hepatol. 2015 Jun 18;7(11):1509-20. doi: 10.4254/wjh.v7.i11.1509. World J Hepatol. 2015. PMID: 26085910 Free PMC article. Review.
-
Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.Drugs. 2008;68(10):1385-414. doi: 10.2165/00003495-200868100-00004. Drugs. 2008. PMID: 18578558 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical